Clearing the smoke: What do we know about adolescent cannabis use and schizophrenia?

Matthew N. Hill, PhD

Hotchkiss Brain Institute, Departments of Cell Biology and Anatomy & Psychiatry, University of Calgary, Calgary, Alta., Canada

While cannabis has been used as a recreational drug in many cultures around the world for centuries, it is only recently that we have begun to understand the biology of how this drug affects the brain. The discovery of the primary components of the endocannabinoid system (the cannabinoid CB1 and CB2 receptors and the endogenous ligands anandamide and 2-arachidonoylglycerol) in the late 1980s and early 1990s allowed for discrete and focused research to occur. In the last 25 years, it has been determined that many of the prototypical effects of cannabis use (increased feeding, sedation, reduced anxiety, reduced blood pressure) mimic the actions of endocannabinoid signalling. That being said, many of the effects of cannabis remain a mystery.

The past few decades have been rife with debate regarding the safety and medical utility of cannabis, little of which has actually been rooted in scientific evidence. The extremes of these opinions state that cannabis is a completely innocuous and harmless substance, or that it is a highly dangerous drug whose use provokes a series of adverse health complications. While both of these opinions are for the most part inaccurate, these unfortunately are the types of debates that often occur in a political sphere and can have substantial impact on policy decisions. The need for evidence-based decisions to guide cannabis access is imperative given that in the states of Colorado and Washington recreational sale of cannabis is now legal and that in Canada there is currently substantial revision and overhaul occurring with the medical marijuana program. While many conditions, including lung cancer and cardiac arrhythmias, have been at the forefront of the cannabis safety debate for some time, interestingly the discussion has predominantly moved to psychiatry — specifically the association between adolescent cannabis use and the development of schizophrenia.

The first study that brought this association to the forefront of the research community was a paper published in Lancet in 1987 that demonstrated a significant association between cannabis use and the development of schizophrenia in a 15-year longitudinal study of more than 45,000 healthy Swedish army conscripts. Individuals who consumed a high level of cannabis (defined as use of cannabis on more than 50 occasions by the age of 18 years) had a greater risk of schizophrenia developing. This finding was interesting, as several historical reports had documented psychotic-like reactions to cannabis, suggesting that there may be a basis for associating cannabis use with the development of schizophrenia. In the decades that followed, several other reports confirmed this association (see the reviews by Malone and colleagues, D’Souza and colleagues and Arsenault and colleagues); that is, when examined retrospectively, individuals in whom schizophrenia had developed exhibited a higher level of cannabis use, often during adolescence. Based on this association, several schools of thought formed: 1) cannabis causes schizophrenia, 2) cannabis acts as a specific risk factor for provoking schizophrenia, and 3) cannabis is used as self-medication.

So what does the science actually tell us? First, the hypothesis that cannabis can cause schizophrenia de novo is essentially without evidence. Although it is true that administration of very high doses of tetrahydrocannabinol (THC), the psychoactive constituent of cannabis, to healthy individuals can produce psychotic-like symptoms transiently, these symptoms subside very quickly and are not representative of a bona fide psychiatric condition. More so, within the Western world, cannabis use went from essentially nonexistent before the 1950s to extremely prevalent in the 1960s and 1970s. Despite this dramatic shift in cannabis use at a societal level, the prevalence of schizophrenia has largely remained stable.

With respect to the self-medication hypothesis there is conflicting evidence. Several reports have documented that cannabis consumption in people with schizophrenia is associated with a reduction in negative and cognitive symptoms (although this is often coupled with a significant increase in positive symptoms). The argument is that since conventional antipsychotic medications do not manage negative symptoms well, cannabis is an adjunct that patients use to
attenuate their negative symptoms. Consistent with this, there are significantly higher rates of cannabis use in people with schizophrenia than in the general population. The major problem with this hypothesis is that both prospective and retrospective studies have reliably found that cannabis use typically precedes the onset of clinical symptoms, arguing against the hypothesis that this association is purely driven by the attempt to manage symptoms.

The most parsimonious hypothesis is that cannabis acts as a specific risk factor that can provoke the onset of a psychotic episode in individuals who are already vulnerable to schizophrenia. However, in the majority of teenagers who use cannabis, schizophrenia does not develop, suggesting that high-risk adolescent exquisitely sensitive to the effects of cannabis. Specific gene polymorphisms, such as ones within the COMT or AKT1 genes seem likely candidates, although a single polymorphism is unlikely to explain this association. Elucidating these factors should be a major focus of ongoing research.

Where does this knowledge take us and how does it inform the cannabis debate? What can be said is that the extreme opinions on this subject are not rooted in science. There is little evidence that, at a population level, cannabis use during adolescence is a primary contributing factor in the development of psychiatric illness. In fact, it has even been suggested that at a societal level, the prevention of 3000–4000 adolescents from consuming cannabis may prevent only 1 case of psychosis from emerging. At the same time, however, there is evidence that in high-risk populations, cannabis can be highly adverse, so arguments claiming that cannabis is innocuous are equally flawed. Health Canada has recently compiled a document reviewing the science regarding the potential benefits and adverse effects of cannabis for an array of medical conditions, including psychiatric illnesses, to provide an evidence-based compendium for physicians and medical practitioners (www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf). Ideally, documents such as this will be used to guide and influence policy decisions and regulatory warnings regarding the accessibility of cannabis to the public as well as consider the age of the individual (as well as family history and risk factors) before access to cannabis is granted. More so, once a diagnosis of schizophrenia is present, cannabis use is clearly adverse and is related to medication nonadherence, accelerated gray matter loss and worse long-term prognosis. As such, regardless of age, any individual with a diagnosis of schizophrenia should be warned of these nontrivial issues, and the contraindication of cannabis with this condition should be given substantial consideration.

References


32. Linszen DH, Dingemans PM, Lenier ME. Cannabis abuse and the course of recent-onset schizophrenia disorders. *Arch Gen Psychiatry* 1994;51:273-9.